John Hoekman - 27 Apr 2021 Form 4/A - Amendment Insider Report for IMPEL NEUROPHARMA INC

Role: Chief Scientific Officer
Signature: /s/ John Leaman, M.D. as attorney-in-fact
Issuer symbol: N/A
Transactions as of: 27 Apr 2021
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 07 Jun 2021, 16:57:58 UTC
Date Of Original Report: 29 Apr 2021
Next filing: 26 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMPL	Common Stock	Conversion of derivative security	$0	+4,253	+4.1%	$0.000000	108,496	27 Apr 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMPL	Series A-2 Preferred Stock	Conversion of derivative security	$0	-69,657	-100%	$0.000000^*	0	27 Apr 2021	Common Stock	4,253		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This amended Form 4 is being filed solely to correct an inadvertent error in the number of shares of common stock acquired in connection with the conversion of shares of Series A-2 Preferred Stock held by the reporting person from 4,523 shares to 4,253 shares.
F2	The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-254999) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.

Content

This amended Form 4 is being filed solely to correct an inadvertent error in the number of shares of common stock acquired in connection with the conversion of shares of Series A-2 Preferred Stock held by the reporting person from 4,523 shares to 4,253 shares.

The shares of the issuer's Series A-2 Preferred Stock automatically converted on a 16.37332-for-one basis into shares of the issuer's Common Stock on April 27, 2021 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-254999) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.